Skip Navigation

JNCI Journal of the National Cancer Institute 1988 80(1):14-20; doi:10.1093/jnci/80.1.14
© 1988 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Moscow, J. A.
Right arrow Articles by Cowan, K. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moscow, J. A.
Right arrow Articles by Cowan, K. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 80, No. 1, 14-20, March 2, 1988
© 1988 Oxford University Press

Multidrug Resistance1

Jeffrey A. Moscow, Kenneth H. Cowan2

2Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute Bethesda, MD 20892.

The ability of malignant cells to develop resistance to cytotoxic drugs poses a major obstacle to the ultimate success of cancer therapy. While some mechanisms of resistance allow cells to survive exposure to a single agent, the phenomenon of multidrug resistance (MDR) confers upon cells the ability to withstand exposure to lethal doses of many structurally unrelated antineoplastic agents. MDR has been strongly linked to the overexpression of a membrane-associated glycoprotein, P-glycoprotein, which appears to play a role in drug efflux. However, several lines of evidence suggest that other mechanisms of resistance are involved in MDR; biochemical similarities observed in a human breast cancer cell line after the acquisition of MDR and in carcinogen-induced rat preneoplastic hepatic nodules indicate that changes in regulation of phase I and phase II drug-metabolizing enzymes may also play a role in MDR. An atypical pattern of MDR has been characterized and related to altered topoisomerase activity. Improvement in current cancer chemotherapy may be achieved by interfering with the regulation and expression of mechanisms of MDR. [J Natl Cancer Inst 1988;80:14–20]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Cell Physiol.Home page
X. Zheng, F. Chu, P. M. Chou, C. Gallati, U. Dier, B. L. Mirkin, S. A. Mousa, and A. Rebbaa
Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism
Am J Physiol Cell Physiol, January 1, 2009; 296(1): C65 - C74.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
K. Asakura, H. Uchida, H. Miyachi, H. Kobayashi, Y. Miyakawa, S. D. Nimer, H. Takahashi, Y. Ikeda, and M. Kizaki
TEL/AML1 Overcomes Drug Resistance Through Transcriptional Repression of Multidrug Resistance-1 Gene Expression
Mol. Cancer Res., June 1, 2004; 2(6): 339 - 347.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. Jolly and R. I. Morimoto
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
J Natl Cancer Inst, October 4, 2000; 92(19): 1564 - 1572.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. L. Fine, T. C. Chambers, and C. W. Sachs
P-Glycoprotein, Multidrug Resistance and Protein Kinase C
Oncologist, August 1, 1996; 1(4): 261 - 268.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. D. Smith and X. Zhang
Mechanism of Action of Cryptophycin
J. Biol. Chem., March 15, 1996; 271(11): 6192 - 6198.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. D. Smith and J. T. Zilfou
Circumvention of P-glycoprotein-mediated Multiple Drug Resistance by Phosphorylation Modulators Is Independent of Protein Kinases
J. Biol. Chem., November 24, 1995; 270(47): 28145 - 28152.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.